Siemens Healthineers at AACC 2016

68th AACC Annual Scientific Meeting & Clinical Lab Expo

Siemens Healthineers at AACC 2016

Earn CE credits at clinical talks and attend our workshops.

Visit AACC to experience the clinical expertise Siemens Healthineers has to offer, both in our sponsored educational workshops and our poster displays.

Educational Workshops

Registration is now open for our hotel workshops. Click below for more information.

Tuesday, August 2: Hotel Workshop

Individualized Quality Control Plan (IQCP): What Does It Mean For You?

Marriott Philadelphia Downtown
Grand Ballroom – Salon G
7:00-8:30 a.m.
Register now!

Christine Arruda, Senior Product Specialist, Critical Care
Siemens Healthineers


Workshop Objective:
In this workshop, we will provide attendees with guidance to help them meet IQCP requirements and review materials available from Siemens Healthineers. They will also obtain advice specific to their lab in a Q&A session at the end of the event.

After this workshop, participants will:

  • Understand IQCP as it relates to your facility.
  • Recognize the tools from Siemens Healthineers that are available to customers.
  • Address specific concerns or questions regarding what customers can expect with these changes. 

Preview the Educational Workshop:

Individualized Quality Control Plan (IQCP): What Does It Mean For You?

Speaker Bio:

Christine Arruda is currently senior product specialist for Siemens Healthineers’ Critical Care business, responsible for the growth and quality of critical care products in the U.S. Prior roles include product marketing manager and first- and second-level support in the U.S. Technical Solutions Center. She began her career as an ASCP-certified medical technologist and holds a BS degree from Salve Regina University in Newport, RI.

Wednesday, August 3: Hotel Workshop

Troponin Evolution or Revolution? Implications for Patient Care

Marriott Philadelphia Downtown
Grand Ballroom – Salon F
7:00-8:30 a.m.
Register Now!

Alan Wu, PhD, San Francisco General Hospital, San Francisco, CA
Sara Collins, MD, FACC, Capital Cardiology Consultants, P.C., Washington, DC


Workshop Objective:

The troponin assay has undergone tremendous changes in terms of sensitivity since its inception. A media storm surrounds the newest assays, but is higher sensitivity the key to making a sound clinical decision?

Upon completion of this workshop, participants will be better equipped to understand the implications of sensitivity in troponin assays: the efficacy of contemporary sensitive assays, clinically usable assays, and new higher sensitive assays as well as the clinical implications for diagnosis within the changing troponin dynamic.

Speaker Bios:

Alan H.B. Wu, PhD, DABCC, is chief of clinical chemistry and toxicology at San Francisco General Hospital and professor of laboratory medicine, University of California, San Francisco. He received BS degrees in chemistry and biology at Purdue University, West Lafayette, Indiana, and a PhD degree in analytical chemistry at the University of Illinois, Champaign-Urbana, Illinois. He completed a postdoctoral fellowship in clinical chemistry at Hartford Hospital and is certified by the American Board of Clinical Chemistry in clinical chemistry and toxicological chemistry. Dr. Wu has written four books consisting of short stories designed to promote the value of the clinical laboratory to the general public.


Dr. Sara D. Collins, MD, FACC, is certified as a Diplomate of the Board of Internal Medicine. She is a Fellow of the American College of Cardiology, Member of the National Medical Association, Association of Black Cardiologists, and the Society for Cardiovascular Angiography and Interventions. She has conducted research on a variety of subjects, including gender and racial disparities in cardiovascular disease and is widely published in several peer-reviewed medical journals. Her interests include transradial cardiac catheterization and women’s cardiovascular health.


Wednesday, August 3: Hotel Workshop

Updating the Hemostasis Laboratory- New Instruments for Streamlining Workflow and Inclusion in Multidisciplinary Automation

Marriott Philadelphia Downtown
Grand Ballroom – Salon H
7:00-8:30 a.m.
Register Now!

Speakers and Topics:
Dr. David Good, Kingston General Hospital, Kingston, ON, Canada
Benefits of Preanalytical Assessment for Hemostasis Testing

Don Manning, Brant Community Healthcare System, Brantford, ON, Canada
Automation of Hemostasis Testing for Enhanced Multidisciplinary Workflow

Dr. Michael Weik, Siemens Healthineers, Marburg, Germany
Multicenter Validation of the Sysmex® CS-2100i and CS-5100 Systems in the U.S.

Workshop Objective:
Facing shrinking budgets, growing workloads, and an increasing number of tests per sample, labs are looking for ways to automate STAT and routine hemostasis testing while streamlining complex, multidisciplinary workflows.

Additionally, preanalytical errors in hemostasis testing have a major impact on TAT, workflow efficiency, and the accuracy and quality of results, thereby impacting patient care. Today’s healthcare providers need automated, standardized preanalytical sample integrity checks, automation connectivity, and result comparability to simplify testing across multisite labs.

This workshop aims to address these issues and share approaches that hemostasis labs can use to overcome workflow challenges and achieve better patient outcomes.

After this workshop, participants will:

  • Understand the value and benefits of preanalytical sample integrity checks in hemostasis testing
  • Understand the different considerations when automating hemostasis testing and enhancing multidisciplinary workflow
  • Know more about ways to simplify hemostasis testing in multisite labs 

Preview the Educational Workshop:

Updating the Hemostasis Laboratory—New Instruments for Streamlining Workflow and Inclusion in Multidisciplinary Automation.

Speaker Bios:

Dr. David Good, MD, FRCPC, is the service chief for hematopathology and the director of the hematology, hemostasis, and flow cytometry laboratories at Kingston General Hospital as well as assistant professor in the Department of Pathology and Molecular Medicine at Queen’s University in Kingston, Ontario, Canada. Dr. Good originally trained as a laboratory technologist, earned BSc and MD degrees at the University of Alberta, and completed a two-year fellowship in lymphoma pathology at the BC Cancer Agency in Vancouver.

Don Manning is the value stream leader for care support at the Brant Community Healthcare System, Brant, Ontario, Canada, overseeing laboratory services, medical imaging, cardiac diagnostics, EMG, pulmonary function, pharmacy, infection prevention and control, and medical devices reprocessing. He was a co-recipient of the inaugural BD Preanalytical Excellence Award, holds a certificate in modern management, and is a Lean/Six Sigma yellow belt. He holds an ART (Advanced Registration) in biochemistry.

Dr. Michael Weik heads two Clinical Affairs groups (Hemostasis Evaluation and Infectious Disease Evaluation) at Siemens Healthineers. His current principal areas of responsibility are planning, conducting, and supervising studies that contribute to the registration of Sysmex® CS Systems and Siemens applications in the U.S. Dr. Weik holds a PhD in human biology.

Wednesday, August 3: Exhibit Floor Workshop

Current Laboratory Trends in Successful Graves’ Disease Management

Theatre 1
10:15 a.m.

Professor Damien Gruson, Laboratory of Clinical Endocrinology, Cliniques Universitaires Saint Luc, Brussels, Belgium

Workshop Objectives:
Hyperthyroidism affects approximately 1.5% of the worldwide population. Graves’ disease is the most common cause of hyperthyroidism and accounts for 60–80% of all cases. Graves’ disease is an autoimmune disorder caused by the thyroid-stimulating antibody, which stimulates the thyroid gland to synthesize and secrete excess thyroid hormone. Being able to quickly and accurately diagnose the cause of hyperthyroidism is critical to the quality of patient care.

In order to choose the right diagnostic tools to assess the status of Graves’ disease patients, it is critical to understand the role of the various thyroid tests available. A fast, accurate diagnosis and careful monitoring are essential to ensure proper patient management.

  • Understand the latest trends in how clinicians diagnose and monitor Graves’ disease
  • Review the latest diagnostic tools recommended for proper differential diagnosis of hyperthyroidism and patient-monitoring challenges
  • Learn how the Thyroid Stimulating Immunoglobulin (TSI) assay can lead to faster, more accurate diagnosis and more efficient and less costly patient care


Speaker Bio:

Professor Damien Gruson was awarded his degrees of pharmacist and specialist in laboratory medicine from the Catholic University of Louvain, Brussels, Belgium. He joined the Department of Laboratory Medicine of the St-Luc University Hospital in 2008. He is now associate laboratory director and lead for endocrine biology. He is also member of the research unit on endocrinology diabetes and nutrition at the Catholic University of Louvain.

Pr. D. Gruson has published numerous articles in several international peer-reviewed journals. He is a member of the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) Communication and Publication Division, the IFCC task force for young scientists (chair from 2010 to 2012 and now consultant), and the IFCC Committee on Distance Learning. He is also a member of the Lipoproteins and Cardiovascular Diseases working group of the American Association of Clinical Chemistry.

Wednesday, August 3: Exhibit Floor Workshop

Natriuretic peptides: Understanding your Options

Theatre 2
1:00 p.m.

Robert H. Christenson, PhD, University of Maryland, Baltimore, MD

Workshop Objective:
Natriuretic peptides play an integral role in the diagnosis of congestive heart failure. Laboratories today have the ability to choose between NT-proBNP and BNP assays to support the testing needs of their patient population.

After this workshop, participants will have a clear understanding of the differences and similarities between NT-proBNP and BNP assays, the proper utility of natriuretic peptides, and the impact on reimbursement.

Speaker Bio:

Robert H. Christenson, PhD, DABCC, FACB, is the current president of the American Association for Clinical Chemistry (AACC). He is currently professor of pathology and professor of medical and research technology at the University of Maryland School of Medicine in Baltimore. He is a member of the editorial boards of Clinical Chemistry and the Journal of Clinical and Laboratory Analysis and associate editor of Clinical Biochemistry.


Educational Posters
This year, Siemens Healthineers is presenting more than 20 posters at AACC. Poster sessions are open to all full conference attendees.

See a list of our AACC posters.

Poster NumberPoster Title
Next Generation System
B-018Optimized Handling of Every Tube through Machine-Vision-Guided Automation
B-017Process Management Opportunities for Lab IT Solutions
B-025Next generation Immunoassay Analyzer: Performance Evaluation of the TSH Assay
B-299Next generation Chemistry Analyzer: Performance Evaluation of the Albumin BCP Assay
B-041Next generation Chemistry Analyzer: Performance Evaluation of the Integrated Multisensor Technology Na, K, and Cl Assays
Clinical Excellence
A-243Assessment of Heterophilic Antibody Interference in the ADVIA Chemistry Hemoglobin A1c_3 Assay
A-183Performance Evaluation of the Anti-Mullerian Hormone Assay on the ADVIA Centaur® XP Immunoassay System
B-066Performance Evaluation of the CMV IgG Assay on the ADVIA Centaur® XP Immunoassay System
B-075Performance Evaluation of the Herpes-I IgG and Herpes-II IgG Assays on the ADVIA Centaur® XP Immunoassay System
A-075Performance Evaluation of the High Sensitivity Cardiac Troponin I Assay on the ADVIA Centaur® XP Immunoassay System
A-193Performance Evaluation of an IGFBP-3 Assay on the ADVIA Centaur® XP Immunoassay Systems
A-203Comparison of Biotin Interference between the ADVIA Centaur® Immunoassay and Roche Modular E170 Systems
A-084Performance Evaluation of the NT-proBNP Assay Using Acridinium Ester Technology on the ADVIA Centaur® XP Immunoassay System
A-316Performance Evaluation of the PIGF and sFLT-1 Assays on the ADVIA Centaur® XP Immunoassay System
A-230Performance Evaluation of the Testosterone II Assay on the ADVIA Centaur® XP Immunoassay System
B320New Emit II Plus Buprenorphine Assay with 5 ngmL Cutoff
A-396Comparison of a LOCI® Vitamin D Total assay* for the Dimension® EXL™ to CDC-certified assays
A-192MMULITE® 2000/XPi IGF-I Assay Restandardization to the 1st WHO IS for Insulin-like Growth Factor-I, NIBSC Code 02/254
A-236Determination of Reference Intervals in Apparently Healthy Pediatric Subjects for the IMMULITE® Thyroid and ADVIA Centaur® TSH3UL Assays
B-020Multicenter Study of the Sysmex® CS-2100i and CS-5100 Systems Compared to the Sysmex CA-1500 System Using Siemens Healthineers Reagents
A-286Comparative Study of the Sysmex® CS-2100i and CS-2500 Coagulation Analyzers
A-292Performance Evaluation of the INNOVANCE® Heparin Assay
A-133A qRT-PCR Diagnostic System to Monitor Toca 511, a Cancer-selective Gene Therapy for the Treatment of Patients with Recurrent High-grade Glioma
A-040Development of RT-qPCR Gene Expression Assays for Multiple New Cancer Therapies
B-201New Molecular Assays for the Simultaneous Detection of Gastric Pathogens Using the VERSANT MiPLX Solution